Post by Andreas Konieczny

Thoughts on AI for brainstorming ADC development During a few days of planned downtime I am catching up on some reading and brainstorming new ideas. I've found AI platforms to be invaluable companions in this exploratory journey to validate concepts and conduct preliminary research. But, you know .... fact-checking! This is particularly crucial when researching recent developments in solid tumor ADCs, where I've noticed consistent inaccuracies across various AI platforms. Will now try to build a custom GPT based on recent literature just for fun. Can you spot the mistakes? 'using antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd), rovalpituzumab tesirine (R-DXd), and' 'For tumors expressing DLL3, transition to R-DXd if T-DXd is ineffective or if there is disease progression.' 'R-DXd: For patients with HER3 expression and limited options, R-DXd can provide a targeted approach to HER3-driven growth.'